Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient sur...

Full description

Saved in:
Bibliographic Details
Published in:Journal of hematology and oncology 2021-07, Vol.14 (1), p.115-115, Article 115
Main Authors: Su, Christopher T, Ye, J Christine
Format: Article
Language:English
Subjects:
Animals
Antibodies
Antibodies, Bispecific - therapeutic use
Antigens
Antineoplastic Agents, Immunological - therapeutic use
Biological products
Bispecific antibodies
Bispecific antibody
Cancer therapies
CAR-T
Care and treatment
Chimeric antigen receptor
Chimeric antigen receptors
Clinical trials
Development and progression
FDA approval
First in human trials
Hematology
Humans
Immunoconjugates - therapeutic use
Immunomodulation
Immunotherapy
Immunotherapy - methods
Immunotherapy, Adoptive - methods
Innovations
Lymphocytes
Lymphocytes T
Monoclonal antibodies
Multiple myeloma
Multiple Myeloma - immunology
Multiple Myeloma - therapy
Neoplasm Recurrence, Local - immunology
Neoplasm Recurrence, Local - therapy
Neurotoxicity
Oncology
Review
T cells
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The pace of innovation of multiple myeloma therapy in recent years is remarkable with the advent of monoclonal antibodies and the approval of novel agents with new mechanisms of action. Emerging therapies are on the horizon for clinical approval with significant implications in extending patient survival and advancing closer to the goal of a cure, especially in areas of immunotherapy such as chimeric antigen receptor T cells, bispecific T cell engager antibodies, antibody drug conjugates, newer generations of monoclonal antibodies, and small molecule inhibitor and modulators. This review provides an update of current myeloma therapeutics in active preclinical and early clinical development and discusses the mechanism of action of several classes of novel therapeutics.
ISSN:1756-8722
1756-8722
DOI:10.1186/s13045-021-01109-y